Lumos Pharma, Inc. (NASDAQ:LUMO – Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 361,500 shares, a growth of 22.7% from the June 30th total of 294,700 shares. Based on an average daily volume of 34,000 shares, the days-to-cover ratio is presently 10.6 days. Currently, 7.0% of the company’s shares are short sold.
Lumos Pharma Trading Up 1.2 %
Shares of LUMO stock traded up $0.02 on Tuesday, reaching $1.78. The company had a trading volume of 50,415 shares, compared to its average volume of 27,527. The stock has a market cap of $14.47 million, a PE ratio of -0.38 and a beta of 0.72. The company has a 50-day moving average of $2.11 and a 200-day moving average of $2.60. Lumos Pharma has a 12 month low of $1.37 and a 12 month high of $4.55.
Lumos Pharma (NASDAQ:LUMO – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.08). The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.51 million. Lumos Pharma had a negative net margin of 2,434.69% and a negative return on equity of 119.87%. During the same period last year, the company earned ($0.89) earnings per share. Sell-side analysts anticipate that Lumos Pharma will post -3.15 earnings per share for the current year.
About Lumos Pharma
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.
Read More
- Five stocks we like better than Lumos Pharma
- How to Use the MarketBeat Dividend Calculator
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- How to Use Stock Screeners to Find Stocks
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.